Catheter Precision (VTAK) Stock Price, News & Analysis

Catheter Precision, Inc. (VTAK) is a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market. The company is engaged in the design, manufacture and sale of medical technologies intended to improve the treatment of cardiac arrhythmias and to support electrophysiology (EP) procedures. Catheter Precision’s common stock trades on the NYSE American under the ticker symbol VTAK.

According to company disclosures, Catheter Precision concentrates on bringing new solutions to market for cardiac arrhythmia treatment by collaborating with physicians and continuously advancing its products. Its activities are aligned with the surgical and medical instrument manufacturing industry, with a particular emphasis on tools and systems used in EP labs and interventional settings.

Core Products and Technologies

Catheter Precision highlights two primary commercial products in its public information: the VIVO™ (View Into Ventricular Onset) system and the LockeT suture retention device.

The VIVO system is described as a non-invasive 3D imaging technology that enables physicians to identify the origin of ventricular arrhythmias before a procedure. Company materials state that VIVO is engineered to offer non-invasive 3D localization of ventricular tachycardia prior to ablation, helping streamline workflow and reduce procedure time. VIVO has received marketing clearance from the U.S. Food and Drug Administration (FDA) and has the CE Mark for use in certain non-U.S. jurisdictions.

Catheter Precision reports that VIVO has been adopted by hospitals in Europe, with installations at institutions such as Albert Szent‑Györgyi Health Centre (Szeged University Hospital) in Hungary and Dubrava University Hospital in Croatia, following competitive tender processes and clinical evaluations. These placements are presented by the company as milestones in its expansion across Central and Eastern Europe.

The LockeT device is described as a suture retention tool intended to assist in wound closure and hemostasis after percutaneous venous punctures, including those associated with EP procedures. Company statements characterize LockeT as a Class 1 device registered with the FDA that has received CE Mark approval, with regulatory clearance also referenced for Great Britain. Public communications emphasize LockeT’s role in supporting venous closure, aiding in rapid hemostasis, and contributing to workflow efficiency in settings where same‑day discharge is an operational goal.

Catheter Precision notes that LockeT has been introduced into multiple international markets through distribution partnerships and hospital-level adoption. Examples cited by the company include launches and commercial uptake in Switzerland through a distribution agreement with FuMedica AG, expansion into South Africa via HLC Medical, and implementation at Mater Private Hospital in Dublin, Ireland, which is described as Ireland’s largest electrophysiology center.

Business Focus and Market Orientation

Across its disclosures, Catheter Precision consistently describes itself as a medical device company focused on the cardiac electrophysiology marketplace. The company’s products are positioned around EP procedures and cardiac arrhythmia management, with VIVO aimed at non-invasive 3D mapping of ventricular arrhythmias and LockeT aimed at venous access site closure and hemostasis after EP-related punctures.

Catheter Precision states that it collaborates with physicians, including through joint ventures and subsidiaries, to develop and protect intellectual property. For example, the company has announced the allowance of a patent titled “Methods of Ventricular Arrhythmia Localization Using a 3D Model,” which it indicates will be assigned to Kardionav, a joint venture focused on new applications in cardiac ventricular therapies. It has also reported allowance of a patent titled “Neurostimulation Devices and Methods,” to be assigned to Cardionomix, a majority-owned subsidiary oriented toward approaches to cardiac ventricular function and heart failure therapy.

In its public communications, Catheter Precision links these patents to its broader technology portfolio, indicating an intention to pursue additional applications in cardiac care and to maintain ongoing patent filings as part of its strategy.

Regulatory and Exchange Information

Catheter Precision’s securities filings state that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and is listed on the NYSE American under the symbol VTAK. The company has used registration statements on Forms S‑1, S‑3 and S‑8 to facilitate offerings and equity compensation plans, and it incorporates subsequent filings by reference into those registration statements.

In an 8‑K filing, the company reported effecting a reverse stock split of its common stock at a ratio of 1‑for‑19, effective August 15, 2025, with the stock continuing to trade on the NYSE American under the symbol VTAK. The filing explains that the reverse split was implemented, among other reasons, to help the company continue to meet the minimum bid price requirement for continued listing on the NYSE American. The authorized capital stock amounts described in that filing were not changed by the reverse split.

Corporate Actions and Governance

Catheter Precision’s proxy materials and 8‑K filings provide insight into certain corporate actions and governance matters. At its 2025 annual meeting of stockholders, the company reports that stockholders approved, among other proposals, the authority for the board of directors to implement a reverse stock split within a specified range and approved the issuance of shares related to certain warrants and preferred stock, in accordance with NYSE American requirements.

In a subsequent special meeting of stockholders, described in a definitive proxy statement and related 8‑K, Catheter Precision sought and obtained approval to amend its Certificate of Incorporation to increase the number of authorized shares of common stock and to ratify the appointment of WithumSmith+Brown, PC as its independent registered public accounting firm for a specified fiscal year. The proxy materials also outline the procedures for virtual stockholder meetings and voting mechanisms via internet, telephone, or mail.

The company has disclosed the use of at‑the‑market equity offering programs under agreements with a placement agent, and later reported the termination of one such ATM Agreement after selling a substantial portion of the maximum aggregate offering amount. In another 8‑K, Catheter Precision describes amendments to short-term promissory notes held by related parties, extending their maturity dates and summarizing the relationships of the note holders to the company. These disclosures are presented in the context of related party transactions and financing arrangements.

Geographic and Market Expansion

Catheter Precision’s news releases describe a pattern of international expansion for both VIVO and LockeT. For VIVO, the company cites tenders and purchase orders from hospitals in countries such as Hungary and Croatia, along with earlier placements in other European markets referenced in its operational updates. For LockeT, the company reports CE Mark approval, regulatory clearance in Great Britain, and commercial launches in Switzerland, South Africa, and multiple European countries, as well as use in U.S. settings.

In its commentary, Catheter Precision often associates these developments with broader goals of expanding its footprint in international markets and increasing adoption of its technologies in electrophysiology labs, ambulatory surgery centers, and other cardiac care environments. The company’s communications also reference interest from hospitals in several European countries following regulatory approvals.

Financial Reporting and Risk Disclosures

Catheter Precision provides periodic financial updates through press releases furnished on Form 8‑K, summarizing revenue trends and net loss figures for specified reporting periods. In connection with these announcements and other filings, the company includes extensive forward‑looking statements and risk factor discussions, directing readers to the “Risk Factors” sections of its Form 10‑K and Form 10‑Q filings.

These risk disclosures address topics such as the company’s history of operating losses, the need to raise additional capital to continue as a going concern, competition in its markets, reliance on regulatory approvals and clearances for its products, potential impacts from international operations and geopolitical events, and the possibility of strategic transactions that could alter its business focus. The company also notes material weaknesses in internal control over financial reporting and the potential consequences of non-compliance with regulatory requirements.

Stockholder Considerations

Investors researching Catheter Precision (VTAK) through its overview page can use this information as a starting point to understand the company’s focus on cardiac electrophysiology devices, its key products VIVO and LockeT, its exchange listing on NYSE American, and its reported efforts to expand in U.S. and international markets. For detailed, time‑sensitive information on financial performance, capital structure, and risk factors, the company directs readers to its filings with the U.S. Securities and Exchange Commission.